Podium to Practice: ESMO® 2025 – GU: POTOMAC

Podium to Practice: ESMO® 2025 – GU: POTOMAC

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christian Kollmannsberger

Icon Chair Speaker

Speakers

Dr. Sebastien Hotte

Dr. Maria Jiang

Studies / Trials Discussed

LBA108 – Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): final analysis of the phase 3, open-label, randomised POTOMAC trial

Studies/trials discussed:

LBA108 – Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): final analysis of the phase 3, open-label, randomised POTOMAC trial
Tagged